
This Slide: #48 of 100 |
Slide #48. Baxter International Inc. — Chatham Therapeutics
Acquirer:
Baxter International Inc. (NYSE:BAX)
Acquiree:
Chatham Therapeutics
Details:
Baxter International Inc. (NYSE:BAX) and Chatham Therapeutics, LLC, today announced that Baxter has agreed to acquire all of Chatham's outstanding membership interests. As a result of the transaction, Baxter will acquire Chatham's developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia.
Baxter International, through its subsidiaries, provides a portfolio of healthcare products, including acute and chronic dialysis therapies; sterile intravenous solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products, surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices. Co. manages its global operations based on four segments, consisting of the following geographic segments: North and South America, Europe, Middle East and Africa, and Asia-Pacific, and a global segment for its Hill-Rom Holdings, Inc. business.
Baxter International SEC Filing Email Alerts Service
Open the BAX Page at The Online Investor »
|
Open the BAX Page at The Online Investor (in a new window) »

![]() ![]() Get SEC Filing Alerts Get Dividend Alerts ![]() ![]() |
![]() Hold (2.43 out of 4) 1st percentile
(ranked lower than approx. 99% of all stocks covered)
Analysts' Target Price: BAX Stock Forecast Based on Zacks ABR data; powered by Xignite ![]() |
